Noncanonical peptides in complex with MHC class I

Expert Review of Vaccines

Volumn 3, Issue 2, 2004, Pages 151-162

  Apostolopoulos, Vasso ^a   Lazoura, Eliada ^a  

^a AUSTIN RESEARCH INSTITUTE   (Australia)

Author keywords

Cancer; Glycopeptide; Long peptide; Low affinity; MHC class I; MUCI; Noncanonical peptides; Peptide MHC complex; T cells; Vaccine

Indexed keywords

GLYCOPEPTIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MANNAN; MUCIN 1; N ACETYLGLUCOSAMINE; PEPTIDE;

ALGORITHM; AMINO TERMINAL SEQUENCE; BINDING AFFINITY; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CELL ACTIVITY; COMPUTER PROGRAM; CRYSTAL STRUCTURE; GLYCOSYLATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MUTATION; NONHUMAN; OPEN READING FRAME; PREDICTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN STABILITY; PROTEIN STRUCTURE; REVIEW;

HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MODELS, MOLECULAR; PEPTIDES; PROTEIN BINDING; PROTEIN CONFORMATION; VACCINES, SUBUNIT;

EID: 1842786515     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.3.2.151     Document Type: Review

References (105)

1. Apostolopoulos V, Haurum JS, McKenzie IF. MUC1 peptide epitopes associated with five different H-2 class I molecules. Eur. J. Immunol. 27(10), 2579-2587 (1997). Identification of low-affinity, noncanonical tumor-associated peptides.
2. Apostolopoulos V, Karanikas V, Haurum JS, McKenzie IF. Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. J. Immunol. 159(11), 5211-5218 (1997).
3. Apostolopoulos V, Chelvanayagam G, Xing PX, McKenzie IF. Anti-MUC1 antibodies react directly with MUC1 peptides resented by class I H2 and HLA molecules. J. Immunol. 161(2), 767-775 (1998).
4. Daser A, Urlaub H, Henklein P. HLA-B27 binding peptides derived from the 57 kD heat shock protein of Chlamydia trachomatis: novel insights into the peptide binding rules. Mol. Immunol. 31(5), 331-336 (1994).
5. Gao L, Walter J, Travers P, Stauss H, Chain BM. Tumor-associated E6 protein of human papillomavirus Type 16 contains an unusual H-2Kb-restricted cytotoxic T-cell epitope. J. Immunol. 155(12), 5519-5526 (1995).
6. Mandelboim O, Bar-Haim E, Vadai E, Fridkin M, Eisenbach L. Identification of shared tumor-associated antigen peptides between two spontaneous lung carcinomas. J. Immunol. 159(12), 6030-6036 (1997).
7. Apostolopoulos V, Yu M, Corper AL et al. Crystal structure of a noncanonical high affinity peptide complexed with MHC class I: a novel use of alternative anchors. J. Mol. Biol. 318(5), 1307-1316 (2002). First crystal structure of a noncanonical peptide in complex with MHC class I. First demonstration of use of new anchor pockets.
8. Apostolopoulos V, Yu M, Corper AL et al. Crystal structure of a noncanonical low-affinity peptide complexed with MHC class I: a new approach for vaccine design. J. Mol. Biol. 318(5), 1293-1305 (2002). First crystal structure of a low-affinity noncanonical tumor-associated peptide in complex with MHC class I.
9. Apostolopoulos V, McKenzie IF, Wilson IA. Getting into the groove: unusual features of peptide binding to MHC class I molecules and implications in vaccine design. Front. Biosci. 1311-1320 (2001).
10. Apostolopoulos V, Pietersz GA, McKenzie IF. Studies of MUC1 peptides. In: Peptide-Based Cancer Vaccines. Kast M (Ed.), Landes Bioscience, Chapman and Hall, USA, 106-120 (2000).
11. Apostolopoulos V, Yu M, McKenzie IF, Wilson IA. Structural implications for the design of molecular vaccines. Curr. Opin. Mol. Ther. 2(1), 29-36 (2000).
12. Apostolopoulos V, Pietersz GA, McKenzie IF. MUC1 and breast cancer. Curr. Opin. Mol. Ther. 1(1), 98-103 (1999).
13. Zinkernagel RM, Doherty PC. Restriction of in vitro T-cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 248(450), 701-702 (1974).
14. Kindred B, Shreffler DC. H-2 dependence of co-operation between T- and B-cells in vivo. J. Immunol. 109(5), 940-943 (1972).
15. Lipsky PE, Rosenthal AS. Macrophage-lymphocyte interaction. Characteristics of the antigen-independent-binding of guinea-pig thymocytes and lymphocytes to syngeneic macrophages. J. Exp. Med. 138(4), 900-924 (1973).
16. Rosenthal AS, Shevach EM. Function of macrophages in antigen recognition by guinea-pig T-lymphocytes. Requirement for histocompatible macrophages and lymphocytes. J. Exp. Med. 138(5), 1194-1212 (1973).
17. Shevach EM, Rosenthal AS. Function of macrophages in antigen recognition by guinea-pig T-lymphocytes. Role of the macrophage in the regulation of genetic control of the immune response. J. Exp. Med. 138(5), 1213-1229 (1973).
18. Zinkernagel RM, Doherty PC. MHC-restricted cytotoxic T-cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function and responsiveness. Adv. Immunol. 27, 51-177 (1979).
19. Apostolopoulos V, Pietersz GA, McKenzie IF. Cell-mediated immune responses to MUC1 fusion protein coupled to mannan. Vaccine 14(9), 930-938 (1996).
20. Apostolopoulos V, Pietersz GA, Loveland BE, Sandrin MS, McKenzie IF. Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc. Natl Acad. Sci. USA 92(22), 10128-10132 (1995).
21. Germain RN, Margulies DH. The biochemistry and cell biology of antigen processing and presentation. Ann. Rev. Immunol. 11, 403-450 (1993).
22. Harding CV, Song R. Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules. J. Immunol. 153(11), 4925-4933 (1994).
23. Higgins DE, Shastri N, Portnoy DA. Delivery of protein to the cytosol of macrophages using Escherichia coli K-12. Mol. Microbiol. 31(6), 1631-1641 (1999).
24. Zwickey HL, Potter TA. Antigen secreted from noncytosolic Listeria monocytogenes is processed by the classical MHC class I processing pathway. J. Immunol. 162(11), 6341-6350 (1999).
25. Van Kaer L. Major histocompatibility complex class I-restricted antigen processing and presentation. Tissue Antigens 60(1), 1-9 (2002).
26. Williams DB, Watts TH. Molecular chaperones in antigen presentation. Curr. Opin. Immunol. 7(1), 77-84 (1995).
27. Rammensee HG. Chemistry of peptides associated with MHC class I and class II molecules. Curr. Opin. Immunol. 7(1), 85-96 (1995).
28. Bjorkman PJ, Saper MA, Samraoui B et al. The foreign antigen binding site and T-cell recognition regions of class I histocompatibility antigens. Nature 329(6139), 512-518 (1987).
29. Bjorkman PJ, Saper MA, Samraoui B et al. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 329(6139), 506-512 (1987).
30. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351(6324), 290-296 (1991).
31. Jardetzky TS, Lane WS, Robinson RA, Madden DR, Wiley DC. Identification of self peptides bound to purified HLA-B27. Nature 353(6342), 326-329 (1991).
32. Madden DR, Golga JC, Strominger JL, Wiley DC. The structure of HLA-B27 reveals nonamer self-peptides bound in an extended conformation. Nature 353(6342), 321-325 (1991).
33. b. Science 257(5072), 919-927 (1992).
34. b-ovalbumin peptide complex reveals the interplay of primary and secondary anchor positions in the major histocompatibility complex binding groove. Proc. Natl Acad. Sci. USA 92(7), 2479-2483 (1995).
35. Madden DR, Gorga JC, Strominger JL, Wiley DC. The three-dimensional structure of HLA-B27 at 2.1.Å resolution suggests a general mechanism for tight peptide binding to MHC. Cell 70(6), 1035-1048 (1992).
36. Garrett TP, Saper MA, Bjorkman PJ, Strominger JL, Wiley DC. Specificity pockets for the side chains of peptide antigens in HLA-Aw68. Nature 342(6250), 692-696 (1989).
37. Rammensee HG, Friede T, Stevanoviic S. MHC ligands and peptide motifs: first listing. Immunogenetics 41(4), 178-228 (1995). A comprehensive listing of known CTL epitopes and ligands to human and mouse MHC class I molecules.
38. Udaka K, Wiesmuller KH, Kienle S, Jung G, Walden P. Decrypting the structure of major histocompatibility complex class I-restricted cytotoxic T-lymphocyte epitopes with complex peptide libraries. J. Exp. Med. 181(6), 2097-2108 (1995).
39. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50(3-4), 213-219 (1999). A database listing of known CTL epitopes and ligands to human and mouse MHC class I/II molecules. Program to predict canonical peptides from a protein sequence.
40. Stauss HJ, Davies H, Sadovnikova E et al. Induction of cytotoxic T-lymphocytes with peptides in vitro: identification of candidate T-cell epitopes in human papilloma virus. Proc. Natl Acad. Sci. USA 89(17), 7871-7875 (1992).
41. Mandelboim O, Vadai E, Fridkin M et al. Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. Nature Med. 1(11), 1179-1183 (1995).
42. b-low affinity, high affinity and covalently-bound peptides in antitumor vaccination. Immunol. Lett. 70(1), 21-28 (1999).
43. Ostrov DA, Roden MM, Shi W et al. How H13 histocompatibility peptides differing by a single methyl group and lacking conventional MHC binding anchor motifs determine self-nonself discrimination. J. Immunol. 168(1), 283-289 (2002). Crystal structure of a nonanchor peptide in complex with MHC class I.
44. Yague J, Marina A, Vazquez J, Lopez De Castro JA. Major histocompatibility complex class I molecules bind natural peptide ligands lacking the amino-terminal binding residue in vivo. J. Biol. Chem. 276(47), 43699-43707 (2001).
45. Liu X, Dai S, Crawford F et al. Alternate interactions define the binding of peptides to the MHC molecule IA(b). Proc. Natl Acad. Sci. USA 99(13), 8820-8825 (2002).
46. Molano A, Erdjument-Bromage H, Fremont DH et al. Peptide selection by an MHC H-2Kb class I molecule devoid of the central anchor ('C') pocket. J. Immunol. 160(6), 2815-2823. (1998). Demonstration that E pocket can be used as an anchor-pocket when the C pocket is absent.
47. Momburg F, Roelse J, Howard JC et al. Selectivity of MHC-encoded peptide transporters from human, mouse and rat. Nature 367(6464), 648-651 (1994).
48. Androlewicz MJ, Cresswell P. How selective is the transporter associated with antigen processing? Immunity 5(1), 1-5 (1996).
49. Schumacher TN, Kantesaria DV, Heemels MT et al. Peptide length and sequence specificity of the mouse TAP1/TAP2 translocator. J. Exp. Med. 179(2), 533-540 (1994).
50. Roelse J, Gromme M, Momburg F, Hammerling G, Neefjes J. Trimming of TAP-translocated peptides in the endoplasmic reticulum and in the cytosol during recycling. J. Exp. Med. 180(5), 1591-1597 (1994).
51. Momburg F, Roelse J, Hammerling GJ, Neefjes JJ. Peptide size selection by the major histocompatibility complex-encoded peptide transporter. J. Exp. Med. 179(5), 1613-1623 (1994).
52. Bouvier M, Wiley DC. Importance of peptide amino and carboxyl termini to the stability of MHC class I molecules. Science 265(5170), 398-402 (1994).
53. Zhang W, Young AC, Imarai M, Nathenson SG, Sacchettini JC. Crystal structure of the major histocompatibility complex class I H-2Kb molecule containing a single viral peptide: implications for peptide binding and T-cell receptor recognition. Proc. Natl Acad. Sci. USA 89(17), 8403-8407 (1992).
54. Collins EJ, Garboczi DN, Wiley DC. 3D structure of a peptide extending from one end of a class I MHC binding site. Nature 371(6498), 626-629 (1994).
55. Chen Y, Sidney J, Southwood S et al. Naturally processed peptides longer than nine amino acid residues bind to the class I MHC molecule HLA-A2.1 with high affinity and in different conformations. J. Immunol. 152(6), 2874-2881 (1994).
56. Matsumura M, Saito Y, Jackson MR, Song ES, Peterson PA. In vitro peptide binding to soluble empty class I major histocompatibility complex molecules isolated from transfected Drosophila melanogaster cells. J. Biol. Chem. 267(33), 23589-23595 (1992).
57. Matsumura M, Fremont DH, Peterson PA, Wilson IA. Emerging principles for the recognition of peptide antigens by MHC class I molecules. Science 257(5072), 927-934 (1992).
58. Horig H, Young AC, Papadopoulos NJ, DiLorenzo TP, Nathenson SG. Binding of longer peptides to the H-2Kb heterodimer is restricted to peptides extended at their C terminus: refinement of the inherent MHC class I peptide binding criteria. J. Immunol. 163(8), 4434-4441 (1999). Demonstration that 'long' peptides can bind to MHC.
59. Olsen AC, Pedersen LO, Hansen AS et al. A quantitative assay to measure the interaction between immunogenic peptides and purified class I major histocompatibility complex molecules. Eur. J. Immunol. 24(2), 385-392 (1994). Demonstration that 'long' peptides can bind to MHC.
60. Stryhn A, Pedersen LO, Holm A, Buus S. Longer peptide can be accommodated in the MHC class I binding site by a protrusion mechanism. Eur. J. Immunol. 30(11), 3089-3099 (2000). Demonstration that 'long' peptides can bind to MHC.
61. Stevens J, Wiesmuller KH, Walden P, Joly E. Peptide length preferences for rat and mouse MHC class I molecules using random peptide libraries. Eur. J. Immunol. 28(4), 1272-1279 (1998).
62. Speir JA, Stevens J, Joly E, Butcher GW, Wilson IA. Two different, highly exposed, bulged structures for an unusually long peptide bound to rat MHC class I RT1-Aa. Immunity 14(1), 81-92 (2001). Crystal structure of a 13-mer rat peptide in complex with rat MHC class I. The structures shows a large 'bulge' in the center of the peptide.
63. Probst-Kepper M, Stroobant V, Kridel R et al. An alternative open reading frame of the human macrophage colony-stimulating factor gene is independently translated and codes for an antigenic peptide of 14 amino acids recognized by tumor-infiltrating CD8 T-lymphocytes. J. Exp. Med. 193(10), 1189-1198 (2001). Identification of a 'long 14-mer' peptide presented by MHC class I.
64. Eisen HN, Sykulev Y, Tsomides TJ. Antigen-specific T-cell receptors and their reactions with complexes formed by peptides with major histocompatibility complex proteins. Adv. Protein Chem. 49, 1-56 (1996).
65. Gillanders WE, Hanson HL, Rubocki RJ, Hansen TH, Connolly JM. Class I-restricted cytotoxic T-cell recognition of split peptide ligands. Int. Immunol. 9(1), 81-89 (1997).
66. Reddehase MJ, Rothbard JB, Koszinowski UH. A pentapeptide as minimal antigenic determinant for MHC class I-restricted T-lymphocytes. Nature 337(6208), 651-653 (1989).
67. Sette A, Vitiello A, Reherman B et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T-cell epitopes. J. Immunol. 153(12), 5586-5592 (1994).
68. Cibotti R, Kanellopoulos JM, Cabaniols JP et al. Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants. Proc. Natl Acad. Sci. USA 89(1), 416-420 (1992).
69. Vierboom MP, Nijman HW, Offringa R et al. Tumor eradication by wild type p53-specific cytotoxic T-lymphocytes. J. Exp. Med. 186(5), 695-704 (1997).
70. Theobald M, Biggs J, Hernandez J et al. Tolerance to p53 by A2.1-restricted cytotoxic T-lymphocytes. J. Exp. Med. 185(5), 833-841 (1997).
71. Andersen ML, Ruhwald M, Nissen MH, Buus S, Claesson MH. Self-peptides with intermediate capacity to bind and stabilize MHC class I molecules may be immunogenic. Scand. J. Immunol. 57(1), 21-27 (2003).
72. Sette A, Vitiello A, Reherman B et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T-cell epitopes. J. Immunol. 153(12), 5586-5592 (1994).
73. van der Burg SH, Visseren MJ, Brandt RM, Kast WM, Melief CJ. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J. Immunol. 156(9), 3308-3314 (1996).
74. Apostolopoulos V, Yuriev E, Ramsland PA et al. A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor. Proc. Natl Acad. Sci. USA 100(25), 15029-15034 (2003). Demonstration that GalNAc can act as an anchoring residue.
75. +) T-cells primed in vivo. Cell Immunol. 214(1), 89-96 (2001).
76. Tourdot S, Scardino A, Saloustrou E et al. A general strategy to enhance immunogenicity of low-affinity HLA-A2.1-associated peptides: implication in the identification of cryptic tumor epitopes. Eur. J. Immunol. 30(12), 3411-3421 (2000).
77. Gad M, Jensen T, Gagne R et al. MUC1-derived glycopeptide libraries with improved MHC anchors are strong antigens and prime mouse T-cells for proliferative responses to lysates of human breast cancer tissue. Eur. J. Immunol. 33(6), 1624-1632 (2003).
78. Haurum JS, Hoier IB, Arsequell G et al. Presentation of cytosolic glycosylated peptides by human class I major histocompatibility complex molecules in vivo. J. Exp. Med. 190(1), 145-150 (1999). Evidence that glycopeptides are processed and presented by MHC class I in vivo.
79. Haurum JS, Arsequell G, Lellouch AC et al. Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specific cytotoxic T-lymphocytes. J. Exp. Med. 180(2), 739-744 (1994).
80. Kastrup IB, Stevanovic S, Arsequell G et al. Lectin purified human class I MHC-derived peptides: evidence for presentation of glycopeptides in vivo. Tissue Antigens 56(2), 129-135 (2000).
81. b-binding peptides generates carbohydrate-specific, unrestricted cytotoxic T-cells. Eur. J. Immunol. 26(3), 544-551 (1996).
82. b.
83. b.
84. Haurum JS, Tan L, Arsequell G et al. Peptide anchor residue glycosylation: effect on class I major histocompatibility complex binding and cytotoxic T-lymphocyte recognition. Eur. J. Immunol. 25(12), 3270-3276 (1995).
85. Vlad AM, Muller S, Cudic M et al. Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T-cells. J. Exp. Med. 196(11), 1435-1446 (2002).
86. Mouritsen S, Meldal M, Christiansen-Brams I, Elsner H, Werdelin O. Attachment of oligosaccharides to peptide antigen profoundly affects binding to major histocompatibility complex class II molecules and peptide immunogenicity. Eur. J. Immunol. 24(5), 1066-1072 (1994).
87. Saito NG, Paterson Y. Contribution of peptide backbone atoms to binding of an antigenic peptide to class I major histocompatibility complex molecule. Mol. Immunol. 34 (16-17), 1133-1145 (1997).
88. Wilson IA, Fremont DH. Structural analysis of MHC class I molecules with bound peptide antigens. Semin. Immunol. 5(2), 75-80 (1993).
89. Nair DT, Kaur KJ, Singh K et al. Mimicry of native peptide antigens by the corresponding retro-inverso analogs is dependent on their intrinsic structure and interaction propensities. J. Immunol. 170(3), 1362-1373 (2003).
90. Guichard G, Connan F, Graff R et al. Partially modified retro-inverso pseudopeptides as non-natural ligands for the human class I histocompatibility molecule HLA-A2. J. Med. Chem. 39(10), 2030-2039 (1996).
91. Herve M, Maillere B, Mourier G et al. On the immunogenic properties of retro-inverso peptides. Total retro-inversion of T-cell epitopes causes a loss of binding to MHC II molecules. Mol. Immunol. 34(2), 157-163 (1997).
92. Bhasin M, Singh H, Raghava GP. MHCBN: a comprehensive database of MHC binding and nonbinding peptides. Bioinformatics 19(5), 665-666 (2003).
93. Bhasin M, Raghava GP. Prediction of promiscuous and high-affinity mutated MHC binders. Hybrid Hybridomics 22(4), 229-234 (2003).
94. Andersen MH, Tan L, Sondergaard I et al. Poor correspondence between predicted and experimental binding of peptides to class I MHC molecules. Tissue Antigens 55(6), 519-531 (2000).
95. Borras E, Martin R, Judkowski V et al. Findings on T-cell specificity revealed by synthetic combinatorial libraries. J. Immunol. Methods 267(1), 79-97 (2002).
96. Stevens J, Wiesmuller KH, Barker PJ et al. Efficient generation of major histocompatibility complex class I-peptide complexes using synthetic peptide libraries. J. Biol. Chem. 273 (5), 2874-2884 (1998).
97. Ding YH, Smith KJ, Garboczi DN et al. Two human T-cell receptors bind in a similar diagonal mode to the HLA-A/Tax peptide complex using different TCR amino acids. Immunity 8(4), 403-411 (1998).
98. Hausmann S, Biddison WE, Smith KJ et al. Peptide recognition by two HLA-A2/Tax11-19-specific T-cell clones in relationship to their MHC/peptide/TCR crystal structure. J. Immunol. 162(9), 5389-5397 (1999).
99. Speir JA, Garcia KC, Brunmark A et al. Strucural basis of 2C TCR allorecognition of H-2Ld peptide complexes. Immunity 8(5), 553-562 (1998).
100. Website of the National Institute of Health's Bioinformatics and Molecular Analysis Section. www.bimas.dcrt.nih.gov/molbio/hla_bind Accessed March, 2004
101. Website of the SYFPEITHI database of MHC ligands and peptide motifs. www.syfpeithi.bmi-heidelberg.com/scripts/MHCServer.dll/home.htm Accessed March, 2004
102. Website of the Walter and Eliza Hall Institute of Medical Research www.wehih.wehi.edu.au/mhcpep/ Accessed March, 2004
103. Vaccinome website www.vaccinome.com Accessed March, 2004
104. Website of the Institute of Microbial Technology www.imtech.res.in/raghava/mmbpred/ Accessed March, 2004
105. Website of the Institute of Microbial Technology www.imtech.res.in/raghava/propred1/index Accessed March, 2004